Incyte Corp. (INCY)
120.97
-0.73
(-0.60%)
USD |
NASDAQ |
Nov 13, 16:00
121.50
+0.53
(+0.44%)
After-Hours: 06:40
Incyte Enterprise Value : 20.86B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 20.86B |
| November 12, 2026 | 21.01B |
| November 11, 2026 | 21.13B |
| November 10, 2026 | 20.72B |
| November 09, 2026 | 21.05B |
| November 06, 2026 | 20.59B |
| November 05, 2026 | 20.26B |
| November 04, 2026 | 21.24B |
| November 03, 2026 | 20.17B |
| November 02, 2026 | 20.67B |
| October 30, 2026 | 20.74B |
| October 29, 2026 | 20.01B |
| October 28, 2026 | 20.02B |
| October 27, 2026 | 19.97B |
| October 26, 2026 | 19.30B |
| October 23, 2026 | 19.79B |
| October 22, 2026 | 20.04B |
| October 21, 2026 | 19.32B |
| October 20, 2026 | 19.97B |
| October 19, 2026 | 19.29B |
| October 16, 2026 | 19.25B |
| October 15, 2026 | 19.29B |
| October 14, 2026 | 18.94B |
| October 13, 2026 | 18.34B |
| October 12, 2026 | 18.90B |
| Date | Value |
|---|---|
| October 09, 2026 | 19.19B |
| October 08, 2026 | 19.18B |
| October 07, 2026 | 19.32B |
| October 06, 2026 | 19.18B |
| October 05, 2026 | 19.47B |
| October 02, 2026 | 19.70B |
| October 01, 2026 | 20.08B |
| September 30, 2026 | 20.94B |
| September 29, 2026 | 20.26B |
| September 28, 2026 | 20.59B |
| September 25, 2026 | 20.40B |
| September 24, 2026 | 20.51B |
| September 23, 2026 | 20.55B |
| September 22, 2026 | 21.01B |
| September 21, 2026 | 20.55B |
| September 18, 2026 | 20.69B |
| September 17, 2026 | 21.15B |
| September 16, 2026 | 20.57B |
| September 15, 2026 | 19.97B |
| September 14, 2026 | 20.06B |
| September 11, 2026 | 19.92B |
| September 10, 2026 | 20.28B |
| September 09, 2026 | 20.83B |
| September 08, 2026 | 20.50B |
| September 04, 2026 | 20.98B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals, Inc. | 6.499B |
| Regeneron Pharmaceuticals, Inc. | 92.19B |
| AbbVie, Inc. | 591.64B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Insmed, Inc. | 26.18B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -784.80M |
| Revenue (Quarterly) | 1.557B |
| Total Expenses (Quarterly) | 2.342B |
| EPS Diluted (Quarterly) | -3.861 |
| Gross Profit Margin (Quarterly) | 91.91% |
| Profit Margin (Quarterly) | -50.40% |
| Earnings Yield | 1.55% |
| Operating Earnings Yield | 2.82% |
| Normalized Earnings Yield | 1.755 |